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Abstract
In the last decade, the estimated annual burden of the flu includes 12,000-52,000 deaths,
140,000-710,000 hospitalizations, and 9 million – 41 million illnesses (Centers for Disease
Control and Prevention: Disease burden of the flu). Influenza A virus can mutate and infect a
variety of different hosts, which results in frequent antigenic changes and even pandemics. This
has led to increased attention on the creation of a universal Influenza A vaccine containing
broader immunogenic coverage than current vaccines. Our research involved detailing the steps
of the cloning process utilizing a consensus neuraminidase antigen. We utilized the pAdEasy
Adenoviral Vector System to insert our consensus neuraminidase gene into a human adenovirus
type 5 (HAdV-5) to create a more immunogenic vaccine.
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1. Introduction
Influenza viruses are a negative-sense single-stranded RNA virus that can mutate at a rapid rate.
This results in yearly strain changes that force updated vaccines to be made each year. The
creation of a universal Influenza vaccine has been at the forefront of vaccine research as current
vaccine models do not demonstrate broad immunogenic coverage. Every season, circulating
strains each season must be predicted months in advance and can sometimes be predicted
incorrectly such as in the 2009 H1N1 pandemic (Centers for Disease Control and Prevention:
2009 H1N1 pandemic). Recent studies have investigated creating mosaic antigens to produce a
more effective Influenza vaccine (Corder 2019 & Weina 2019). Through the creation of an
Influenza vaccine with broader immunogenic capabilities, Influenza vaccinations may only need
to be given once every 5 years, 10 years, or potentially once in a lifetime.

Here we developed a recombinant adenovirus vaccine utilizing the AdEasy Adenoviral Vector
System. The adenoviral vector acts as a delivery system to carry a consensus Influenza A virus
(IAV) neuraminidase antigen in vivo. Neuraminidase (NA) and hemagglutinin (HA) are two
glycoproteins found on the influenza virus membrane (Gamblin 2010) and aid in viral entry and
exit from the host cell during infection. The plasticity of these two main proteins serves as a
major obstacle in creating a broadly cross-reactive vaccine against IAV. A consensus vaccine is
created by determining the average amino acid at each point on a gene and utilizing the most
common amino acid to create a vaccine that promotes a broader immune response.

Adenovirus is a common virus that causes cold-like symptoms. By the age of 10, almost every
child has at least one adenovirus infection (Centers for Disease Control and Prevention:
Adenovirus). Adenovirus is also capable of infecting a wide range of cell types just like the
Influenza A virus.

For this study, we utilized the human adenovirus serotype 5 (HAdV-5) as a vector. The
adenovirus genome is large and is approximately 36kb. This HAdV-5 has had the E1 and E3
genes deleted to render the adenovirus replication defective. With the elimination of the E1 and
E3 genes, the recombinant adenovirus will have up to 7.5kb available for the insertion of foreign
DNA, and it will not allow the virus to replicate itself. We utilized homologous recombination in
Escherichia coli through co-transforming pAdEasy-1 and a shuttle vector carrying our gene. The
genome of the shuttle vector (pShuttle-CMV) is approximately 7.5kb and its cloning capacity is
6.6kb.

2. Materials & Methods

2.1 N1 Neuraminidase Gene Design

To create the NA gene, all complete human Influenza A N1 sequences isolated between 1930
and 2007 with complete amino acid sequences in human hosts were downloaded from the
Influenza Research Database. Duplicate sequences and laboratory strains were excluded. This
resulted in 748 sequences. In 2007, Dr. Eric Weaver utilized this process to create the NA-1

consensus sequence. An in-silico representation of the NA-1 consensus protein sequence was
created with Swiss-Model and visualized in the UCSF Chimera program (Figure I). To visualize
the genetic relation of the NA-1 consensus gene to all other natural sequences, a phylogenetic
tree was constructed in Geneious using the748 sequences initially used in the immunogen design
(Figure II). The gene was then human codon optimized and synthesized by GenScript with the
addition of the KpnI and HindIII restriction sites artificially added to the ends for downstream
cloning processes. The final gene was created in the plasmid pUC57, containing an ampicillin
resistance gene.

2.2 Ligation of pShuttle-CMV and N1 Neuraminidase

To begin, the Genscript-synthesized plasmid was transformed into XL-1 electrocompetent E coli
cells and selected on Luria Broth (LB)-ampicillin plates. One colony was picked from the
pUC57-NA1 consensus transformation and inoculated into a cell culture tube consisting of 4mL
LB media (1 liter of LB media contains 10 grams of Tryptone, 10 grams NaCl, 5 grams yeast
extract, and the addition of distilled water up to the 1-liter volume) and 4μL Ampicillin (used in
a 1:1000 ratio) (Bradburn 2019). The tube was place at 37°C conditions and shook overnight at
225 revolutions per minute (RPM). The next day, a glycerol stock of the pUC57-NA1 was made
through the addition of 250μL of 60% glycerol and 750μL of the bacteria to a cryotube. The
glycerol stock was vortexed and placed at -80°C for long-term storage.

The remaining culture was miniprepped using the QIAprep spin miniprep kit with the following
modifications: bacteria were spun for 1 minute at max speed in step 1, bacteria were spun for 5

minutes at max speed in step 5, and final DNA isolated eluted in 50μl of double distilled water in
step 10 (QIAPrep Miniprep 2012). The product was vortexed and nanodropped to determine the
concentrations. All minipreps performed in the cloning process utilized the same kit and
modifications applied as previously described.

The product was then digested using restriction enzymes. A restriction enzyme digest enables the
neuraminidase gene to be cut out of the current plasmid so that it can be later introduced into a
new vector. In this case, the consensus neuraminidase gene was to be spliced out of the pUC57NA1 parental plasmid and introduced into pShuttle-CMV. The shuttle vector allows for the
insertion of our gene into pAdEasy-1, as outlined in step 2.3. It is challenging to directly ligate
our gene of interest into pAdEasy-1 as pAdEasy-1 has very few restriction enzyme sites which
results in the need for a shuttle vector (AdEasy adenoviral vector system).

KpnI and HindIII were the enzymes used in this procedure. The digests of PUC57-NA1
consensus and pShuttle-CMV were done separately but with the same concentrations of the
following components: 10μg DNA, 8μL 10X Cut Smart, 0.5μL KpnI, 0.5μL HindIII, and 21μL
double deionized water to create a total volume of 80μL. A 10μg concentration of the DNA was
desired, and the 10X Cut Smart used in this procedure consisted of 10% of the total volume. The
pShuttle-CMV digest and the pUC57-NA1 consensus digest were both placed at 37°C overnight
for complete digestion.

The two restriction digests were run on a 0.8% agarose gel at 130 volts for 35 minutes, and the
digested DNA can be seen in Figure III, lanes 2 and 4. The QIAquick Gel Extraction Kit was

used to extract the digested pShuttle-CMV and the neuraminidase gene of interest, and the excise
fragements were then purified with a Gel Cleanup Kit (Qiaquick Gel Extraction Kit and
QIAquick PCR & Gel Cleanup Kit). The products were then nanodropped to determine the
260/280 values and DNA concentration.

The extracted products were then used in a ligation. A ligation utilizes a ligase to join two
fragments of DNA. The enzyme used in this procedure was T4 ligase. Three different ligation
concentrations were used to join the pUC57-NA1 consensus gene into pShuttle-CMV. Ratios of
3:1, 1:1, and 1:3 were prepared. The ligations were incubated at room temperature for 2 hours
and then placed at 4°C overnight.

After the ligation, the three different concentrations were transformed via electroporation into
XL-1 electrocompetent E. coli bacterial cells. Electroporation uses electricity to create temporary
pores in bacterial membranes so that foreign nucleic acid material can enter the cells. 5μL of
each ligation, 20μL XL-1 bacterial cells, and 80μL of double deionized water were added to an
electrocuvette. A control transformation was also performed which included 20μL XL-1
bacterial cells, and 80μl of double deionized water. A control is used to ensure that there is no
contamination or issues with the materials used. If there is a high background on the negative
control plate, that could indicate there are problems with the bacterial cells or antibiotics in the
agar plates. The samples were placed in the electroporator at 2500 volts. After electroporation,
350μL of Super Optimal broth with Catabolite repression (SOC) media was added to each
electrocuvette. SOC media is a nutritionally rich media that enables the damaged cells to recover
after the transformation. The products were then transferred to microtubes and shook for 2 hours

at 37°C and 225 RPM. 50μL of each transformation product was plated on a LB-Kanamycin
plate and then incubated overnight at 37°C. In this step, kanamycin was used as a selective
antibiotic to only allow successfully ligated pShuttle-CMV-NA1 consensus products to grow on
the plates.

Colonies from each plate were miniprepped, confirmation digested, and run on a gel. As seen in
Figure IV, all six colonies selected contained both pShuttle-CMV and the NA1-consensus insert
(lanes 1-6). The same methods were used as explained above for the miniprep, restriction digest,
and gel electrophoresis from the prior experiment. We used the QIAspin midiprep kit to isolate
the DNA from the XL-1 cells. Performing a midiprep at this step enabled us to collect a higher
concentration and amount of pShuttleCMV-NA1-consensus prior to the upcoming cotransformation step. The Qiagen midiprep protocol was followed with the following
modifications: spun for 5 minutes at 6000xg in step 6 and eluted with 1mL of 50°C ddH2O in
step 17 (Qiagen plasmid Mini, MIDI, and Maxi Kits (EN))

2.3 Co-transformation into pAdEasy-1

To perform the co-transformation, pShuttle-CMV-NA1 was linearized to insert our gene. 34μL
of DNA, 10μL ddH2O, 5μL Cut Smart, and 1μL of PmeI enzyme were pipetted into a microtube
and incubated at 37°C overnight. After linearization of pShuttle-CMV-NA1, Shrimp Alkaline
Phosphatase (rSAP) (Biolabs) was added to the digest. rSAP is an enzyme that can catalyze the

removal of phosphate groups of 5´ and 3´ ends of the phosphomonoesters in DNA. 1μL of rSAP
was added and incubated at 37°C for 1 hour.

After incubation, the linearized pShuttle-NA1-consensus with removed phosphates was purified
using the QIAquick Polymerase Chain Reaction (PCR) purification kit from QIAGEN with the
following modification: in step 7, the DNA was eluted with 50μL ddH2O instead of Buffer EB
(QIAquick PCR purification kit and QIAquick PCR & gel cleanup kit quick-start protocol).

Then, the purified gene product was co-transformed into BJ5183 E. coli cells. BJ5183 cells are
used because they contain the recA protein and the machinery necessary to perform the
homologous recombination between pShuttle-CMV and pAdEasy-1 (AdEasy adenoviral vector
system).12μL pShuttle-CMV-NA1-consensus, 1μL pAdEasy-1, 20μL BJ5183 cells, and 80μL
ddH2O were added to an electrocuvette and electroporated at 2500 volts. After electroporation,
the product was transferred to a 1.5mL microtube and 350μL of SOC media was added and
shook for 2 hours at 37°C at 225 RPM. 50μL of each transformation product was plated on a
Kanamycin plate and incubated overnight at 37°C. Kanamycin was once again used as a
selective antibiotic to only allow the successful transformants to grow.

2.4 Miniprep DNA and confirmation with restriction enzyme digest

20 bacterial colonies were picked after the co-transformation from the LB/Kan plate and
miniprepped. After nanodropping, a confirmation digest was performed to see if the gene of
interest was successfully inserted into pAdEasy-1. 0.5μL PacI, 2μL 10X Cut Smart, 10μL

pAdEasy-NA1-consensus, and 7.5μL double deionized water were added to a microtube and
incubated at 37°C for 30 minutes. The confirmation digest was run on a 0.5% agarose gel for 30
minutes at 130 volts. This successful transformant can be visualized in Figure V (lane 2). At this
stage, a successful transformation is seen as no band present. The DNA run in lane 2 was utilized
in the subsequent confirmation steps outlined in section 2.5 below.

2.5 Transformation into XL-10-Gold Ultracompetent cells to amplify gene product

To amplify the gene product, the pAdEasy-NA1-consensus was transformed into XL10-Gold
(XL-1) ultracompetent cells. XL-1 cells are deficient in recA and the endonuclease (endA1). The
absence of recA helps maintain the stability of the insert, and endA1 improves the quality of the
miniprepped DNA (AdEasy adenoviral vector system). 20μL pAdEasy-NA1-consensus, 20μl
XL-1 cells, and 80μl ddH2O were added to an electrocuvette and electroporated at 2500 volts.
After electroporation, the same end procedure described in the co-transformation step in 2.3 was
performed.

To confirm that we had the correct product, a miniprep and confirmation digest were performed.
One XL-1 colony was picked from the Kan-LB plate and placed in a cell culture tube with 4mL
of LB media and 4μL kanamycin. The tube shook overnight at 37°C and a restriction enzyme
digest was performed the next day. The concentrations for the digest were as follows: 30μl
pAdEasy-NA1-consensus, 3.3μL 10X Cut Smart, and 0.5μL PacI. The digest was incubated for 1
hour at 37°C and then ran on a 0.8% agarose gel for 30 minutes at 130 volts. Concurrently, an
uncut plasmid was run on the agarose gel to better visualize the successful insertion into the

pAdEasy-1 genome. The appropriate DNA band can be seen in Figure VI, lane 2 as ~5.1kB. A
glycerol stock of the pAdEasy-NA1-consensus in XL-1 cells was prepared by adding 250μL of
30% glycerol and 750μL of the XL-1 bacteria with our gene of interest to a cryotube. The
glycerol stock was vortexed and placed at -80°C.

After confirmation of our gene, we used the QIAspin midiprep kit with the same procedure and
exceptions explained in section 2.2 to increase the amount of the pAdEasy-NA1-consensus DNA
product.

Results
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in blue) has been shown to interact with the light and heavy chain of broadly cross-reactive
antibody 1G01 (Stadlbauer 2019).

Figure II. Phylogenetic Tree of NA-1 consensus antigen (indicated by the red square) (Influenza
research database).
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Figure III. KpnI and HindIII digest and gel extraction of pUC57-N1-Con and pShuttle-CMV.
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Figure IV. Confirmation of pShut-CMV and NA1-Con ligation for insert.
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Figure VI. PacI digestion before transfection.

Figure VII. CsCl Prep after amplification.

Figure VIII. Western Blot of Ad-NA1-Con.

Discussion

Our gene was successfully cloned into the pAdEasy vector system. In Figure V, no bands appear
in lane 2 indicating it was a potential co-transformation success of pAdEasy and pShuttleCMVNA1-Con. The pAdEasy gene is a large genome consisting of 36 kb. This large genomic material
explains why it does not appear in lane 2. Lane 2 also had a very low concentration of 4.8 ng/μL,
explaining the lack of band expression. To confirm that it was truly a co-transformation success
of pAdEasy and pShuttleCMV-NA1-Con, the colonies were re-screened after a transformation
into XL-1 cells. The re-screening of the DNA from lane 2 with a PacI digest indicated a
successful co-transformation did occur with our gene of interest and pAdEasy (Figure VI). The
uncut DNA is significantly above the 21226bp band which matches the genome of pAdEasy

(~36kb), and the cut DNA shows the presence of our insert. Further demonstration of successful
cloning is shown in the CsCl prep and the western blot (Figures VII and VIII).

The implications of this research are vast and could lead to the creation of a universal Influenza
A vaccine that utilizes a consensus neuraminidase. Studies have found that antibody 1G01 binds
to the neuraminidase antigen and the antigen serves as a target for broadly protective antibodies
(Stadlbauer 2019 & Madsen 2020). As neuraminidase is more conserved than hemagglutinin,
neuraminidase could serve as a better target in the future for a universal Influenza vaccine than
previously thought.

Limitations
Cell culture and further experimentation with animals were not performed by myself as I do not
have the credentials to work directly with animals. These steps were completed by graduate
student Erika Petro-Turnquist, including the CsCl preparation and the Ad-NA1-Con western
blot. The research done prior to cell culture was performed by myself and two other
undergraduate students.
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